Informed Prostate Cancer Patient Support

Example of a Hypothetical AI-Generated Clinical Visit Transcript and the Resulting Draft Note. AI Medical Scribes: Should Your Doctor's Notes Keep the Full Conversation? AI Medical Scribes: Should Your Doctor's Notes Keep the Full Conversation? BOTTOM LINE UP FRONT: AI scribes that automatically transcribe doctor visits are being widely adopted across healthcare, but most U.S. hospitals are deleting these valuable transcripts immediately after finalizing patient notes—primarily due to malpractice liability fears. This practice prevents researchers from evaluating AI accuracy, studying diagnostic errors, and advancing medical knowledge, while AI companies retain the data to train future products. Experts argue that with proper safeguards, these transcripts represent "digital gold" for improving healthcare quality and safety. The Rise of AI Medical Scribes Artificial intelligence has entered the exam room. AI scribes—software tools powered by large language models—n...

FDA OKs Blood-Based Test to Help Detect High-Grade Prostate Tumors | MedPage Today FDA Approves New Blood Test to Better Detect Aggressive Prostate Cancer BLUF (Bottom Line Up Front): The FDA has approved IsoPSA, a novel blood test that analyzes PSA at the molecular level to more accurately identify men with aggressive prostate cancer. In clinical studies, the test demonstrated 90% sensitivity for detecting high-grade tumors while potentially reducing unnecessary biopsies by 55%, offering men with elevated PSA a more precise tool for deciding whether to proceed with biopsy. Understanding the New Test Men facing elevated PSA levels now have access to a more sophisticated diagnostic tool following the FDA's December 2025 approval of Cleveland Diagnostics' IsoPSA test. Unlike standard PSA testing, which measures only the total amount of prostate-specific antigen in blood, IsoPSA examines the structural variations (isoforms) of the PSA molecule itself to determine whether eleva...

Lose the Wait: What Happens When Your MRI Meets AI How Patients Are Taking Control Before Their Doctor Appointments BLUF (Bottom Line Up Front) Prostate cancer patients can now request their MRI results immediately after scanning and use large language models like Claude and ChatGPT to understand complex medical terminology before meeting with their doctors. This emerging practice, combined with breakthrough AI systems achieving expert-level accuracy in detecting clinically significant prostate cancer, is fundamentally transforming the patient-doctor relationship from passive recipients to informed partners in care. As of January 2025, over 1,250 AI-enabled medical devices have received FDA clearance, with radiology applications comprising approximately 75% of these approvals. The Two-Week Wait Is Over For decades, the process has been the same: get your prostate MRI, leave the imaging center with nothing but worry, and wait two weeks or more for an appointment to learn your fate....

Supply Breakthrough Accelerates Path to Patients BLUF (Bottom Line Up Front) New research demonstrates that actinium-225 alpha-particle therapy kills prostate cancer cells far more effectively than current lutetium-177 treatments in laboratory studies. Multiple human clinical trials are already underway showing promising safety and response rates. Critically, a supply revolution in 2024-2025 has eliminated the isotope scarcity that once constrained development. However, even the most advanced actinium-225 therapies remain 3-5 years from potential FDA approval. Men with advanced prostate cancer facing treatment decisions today should proceed with proven therapies like Pluvicto rather than waiting, while staying informed about emerging trials. The Physics of More Powerful Cancer Treatment For men with metastatic castration-resistant prostate cancer—the deadliest form of the disease that no longer responds to hormone therapy—a fundamental change in radiation therapy may offer new hop...